These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 2508092)

  • 21. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombolytic therapy: enhancement by platelet and platelet-derived mediator antagonists.
    Willerson JT; Golino P; McNatt J; Eidt J; Yao SK; Buja LM
    Mol Biol Med; 1991 Apr; 8(2):235-43. PubMed ID: 1806765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP; Tschopp TB; Kuhn H; Steiner B; Hadváry P
    J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
    Biemond BJ; Levi M; Coronel R; Janse MJ; ten Cate JW; Pannekoek H
    Circulation; 1995 Feb; 91(4):1175-81. PubMed ID: 7850956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
    Yasuda T; Gold HK; Fallon JT; Leinbach RC; Guerrero JL; Scudder LE; Kanke M; Shealy D; Ross MJ; Collen D; Coller BS
    J Clin Invest; 1988 Apr; 81(4):1284-91. PubMed ID: 2832448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.
    Nicolini FA; Lee P; Malycky JL; Lefkovits J; Kottke-Marchant K; Plow EF; Topol EJ
    Blood Coagul Fibrinolysis; 1996 Jan; 7(1):39-48. PubMed ID: 8845461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T; Gold HK; Leinbach RC; Yaoita H; Fallon JT; Guerrero L; Napier MA; Bunting S; Collen D
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
    Mehta JL; Nichols WW; Saldeen TG; Chandna VK; Nicolini FA; Lawson DL; ter Riet MF
    J Cardiovasc Pharmacol; 1990 Jul; 16(1):112-20. PubMed ID: 1696653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
    J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
    Shebuski RJ; Stabilito IJ; Sitko GR; Polokoff MH
    Circulation; 1990 Jul; 82(1):169-77. PubMed ID: 2114233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA; Mellott MJ; Garsky VM; Shebuski RJ
    Pharmacology; 1991; 42(6):340-8. PubMed ID: 1946598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis.
    Jackson CV; Wilson HC; Growe VG; Shuman RT; Gesellchen PD
    J Cardiovasc Pharmacol; 1993 Apr; 21(4):587-94. PubMed ID: 7681904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
    Nicolini FA; Mehta JL; Nichols WW; Saldeen TG; Grant M
    Circulation; 1990 Mar; 81(3):1115-22. PubMed ID: 1689620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis.
    Schneider J
    Thromb Res; 1991 Dec; 64(6):677-89. PubMed ID: 1798957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion.
    Yao SK; McNatt J; Anderson HV; Eidt J; Cui KX; Golino P; Glas-Greenwalt P; Maraganore J; Buja LM; Willerson JT
    Am J Physiol; 1992 Feb; 262(2 Pt 2):H374-9. PubMed ID: 1539695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model.
    Lefkovits J; Malycky JL; Rao JS; Hart CE; Plow EF; Topol EJ; Nicolini FA
    J Am Coll Cardiol; 1996 Dec; 28(7):1858-65. PubMed ID: 8962577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.
    Feigen LP; Nicholson NS; King LW; Campion JG; Tjoeng FS; Panzer-Knodle SG
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1191-7. PubMed ID: 8263779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
    Yasuda T; Gold HK; Fallon JT; Leinbach RC; Garabedian HD; Guerrero JL; Collen D
    J Am Coll Cardiol; 1989 May; 13(6):1409-14. PubMed ID: 2495318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.
    Prager NA; Torr-Brown SR; Sobel BE; Abendschein DR
    J Am Coll Cardiol; 1993 Jul; 22(1):296-301. PubMed ID: 8509554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator.
    Shebuski RJ; Sitko GR; Claremon DA; Baldwin JJ; Remy DC; Stern AM
    Blood; 1990 Apr; 75(7):1455-9. PubMed ID: 1969293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.